Kura Oncology (KURA) vs Nuvectis Pharma (NVCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Nuvectis Pharma (NVCT) has outperformed Kura Oncology (KURA) over the past year, gaining 218.9% versus a loss of 38.1%. Nuvectis Pharma is the larger company by market cap ($666.8 million vs $634.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KURA | NVCT |
|---|---|---|
| Share price | $6.91 | $19.39 |
| Market cap | $634.88M | $666.80M |
| 1-day change | -5.99% | -2.27% |
| YTD return | -33.49% | +156.82% |
| 1-year return | -38.14% | +218.91% |
| 5-year return | -50.66% | — |
| EPS (TTM) | $-3.30 | $-2.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $67.48M | — |
| Revenue growth (YoY) | +25.24% | — |
| Net income (latest FY) | $-278.67M | $-26.44M |
| Operating margin | -449.94% | — |
| Net margin | -412.95% | — |
| 52-week high | $13.90 | $29.28 |
| 52-week low | $6.75 | $5.77 |
| Distance from 52-week high | -50.29% | -33.77% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +357.60% | +82.57% |
| Average volume | 2.10M | 206.37K |
| Shares outstanding | 91.88M | 34.39M |
| Employees | 260 | 19 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVCT has outperformed KURA by 257.1 percentage points over the past year.
About Kura Oncology
KURA stock →Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
About Nuvectis Pharma
NVCT stock →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
KURA vs NVCT FAQ
Which is bigger, Kura Oncology or Nuvectis Pharma?
Nuvectis Pharma (NVCT) is larger, with a market capitalization of $666.80M compared with $634.88M for Kura Oncology (KURA).
Which stock has performed better over the past year, KURA or NVCT?
NVCT returned +218.91% over the past 12 months, compared with -38.14% for KURA (price return, excluding dividends). Past performance does not predict future results.
Are Kura Oncology and Nuvectis Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.